东陽光药

SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

VOLUNTARY ANNOUNCEMENT (1) PROPOSED INCREASE IN SHAREHOLDING IN THE COMPANY BY THE CONTROLLING SHAREHOLDER AND DIRECTOR; AND (2) ON-MARKET SHARE REPURCHASE

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

(1) PROPOSED INCREASE IN SHAREHOLDING IN THE COMPANY BY THE CONTROLLING SHAREHOLDER AND DIRECTOR

The board (the "**Board**") of directors (the "**Director(s)**") of the Company has been notified by Mr. Zhang Yushuai ("**Mr. Zhang**"), the controlling shareholder of the Company and non-executive Director, of his intention to increase his shareholding in the Company through purchasing shares of the Company ("**Shares**") listed on The Stock Exchange of Hong Kong Limited in the open market by or through entities controlled by him. Mr. Zhang intends to increase between HK$300 million to HK$600 million worth of Shares in the next six months by or through entities controlled by him (the "**Share Increase Plan**"). Subsequently, Mr. Zhang will further increase his shareholding amount by or through entities controlled by him as appropriate based on market conditions.

As of the date of this announcement, Mr. Zhang directly and indirectly through entities controlled by him, holds an aggregate of 293,971,756 Shares, representing approximately 51.11% of the issued Shares (excluding treasury Shares).

The Board believes that the Share Increase Plan reflects Mr. Zhang's firm confidence in the long-term development prospects of the Group and the value of the Company.

Mr. Zhang advised the Company that he will strictly comply with the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the applicable requirements under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Zhang advised that it is not expected that the Share Increase Plan will be implemented in such a way which would trigger a mandatory offer obligation under Rule 26 of The Code on Takeovers and Mergers. The Company will not participate in the Share Increase Plan, nor will it provide any financial assistance for the Share Increase Plan.

(2) ON-MARKET SHARE REPURCHASE

The Board hereby announces that on 20 July 2026, the Company repurchased 817,500 Shares of the Company in the open market (the "**Share Repurchase**") for an aggregate consideration of HK$26,358,936, representing approximately 0.14% of the total issued Shares. The repurchased Shares will be held by the Company as treasury Shares. Subject to compliance with all applicable laws and regulations, the Company may repurchase further shares in accordance with market conditions.

The Board believes that the Share Repurchase in the present market conditions demonstrates the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to the shareholders of the Company (the "**Shareholders**"). The Share Repurchase was conducted under circumstances which the Board considers to be appropriate and in the interest of the Company and the Shareholders as a whole.

Based on information available to the Company and to the best knowledge and belief of the Directors, following implementation of the Share Increase Plan and after the Share Repurchase, the Company will maintain a sufficient public float of issued Shares that satisfies the requirements under with the Listing Rules.

The implementation of the Share Increase Plan is subject to market conditions and compliance with all applicable laws and regulatory requirements. There is no assurance that the Share Increase Plan will be implemented in full or within the proposed timeframe. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
20 July 2026

As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfa, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.